Form 4: UTHR CEO Sells Shares Under 10b5-1 Plan

United Therapeutics CEO Martine Rothblatt exercised stock options and sold resulting shares as part of a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), exercised 9,500 stock options on March 13, 2026, at an exercise price of $146.03 per share.
• Concurrently, Rothblatt sold 9,500 shares of Common Stock in multiple transactions on March 13, 2026, at weighted average prices ranging from $535.4265 to $542.035 per share.
• These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.
• The 10b5-1 plan is set to continue until the earlier of the exercise of 1,734,410 stock options (all expiring on March 17, 2027) or December 31, 2026.
• Following these transactions, Rothblatt directly holds 130 shares of Common Stock and indirectly holds 639,193 shares through various family trusts.
• Rothblatt also beneficially owns 145,000 derivative stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it involves insider selling, the pre-arranged 10b5-1 plan mitigates concerns about opportunistic timing, and the exercise of options at a much lower price than the sale price highlights the stock's appreciation.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, indicating a planned and transparent approach to insider stock sales, reducing concerns about opportunistic timing.
• The exercise of stock options at $146.03 and subsequent sale at prices over $535 demonstrates significant personal gain for the CEO, reflecting the company's stock appreciation.

Negatives

• The sale of 9,500 shares by the Chairperson & CEO represents a reduction in direct beneficial ownership, which could be interpreted as a lack of conviction, although mitigated by the 10b5-1 plan.

Future Outlook

The pre-arranged 10b5-1 trading plan indicates a continued intention for the reporting person to exercise and sell up to 1,734,410 stock options, which expire on March 17, 2027, or until December 31, 2026, whichever comes first.

Management Comments

• "This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025."
• "This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026."

Industry Context

StockSavvy.ai notes that insider transactions, particularly those by top executives like the CEO, are closely watched by investors for signals about management's confidence in the company's future. While sales under a 10b5-1 plan are generally considered less indicative of a negative outlook due to their pre-scheduled nature, the sheer volume of potential future sales outlined in the plan (up to 1.7 million options) suggests a long-term strategy for liquidity and diversification by the executive.

Comparison to Industry Standards

• StockSavvy.ai observes that sales by executives under Rule 10b5-1 plans are a common practice across industries, including biotechnology and pharmaceuticals, for managing personal finances while adhering to insider trading regulations.
• For example, executives at companies like Amgen (AMGN) or Gilead Sciences (GILD) frequently utilize similar plans to systematically monetize vested equity awards.
• The scale of the options involved for Ms. Rothblatt is substantial, reflecting her long tenure and significant equity compensation at United Therapeutics.

Stakeholder Impact

• Shareholders: The sale by the CEO could be perceived negatively by some, but the 10b5-1 plan provides transparency. The significant profit from option exercise demonstrates value creation for long-term shareholders.

Next Steps

• Continued exercise and sale of up to 1,734,410 stock options under the 10b5-1 trading plan.
• The 10b5-1 plan will continue until December 31, 2026, or until all specified options are exercised, whichever is earlier.

Key Dates

Recommendation

The filing details routine insider transactions under a pre-arranged 10b5-1 plan, which are generally not indicative of a change in the company's fundamental outlook. While the CEO is selling shares, this is a planned liquidity event rather than a reaction to new information. Investors should maintain their current position and focus on the company's operational performance and broader market trends rather than this specific insider transaction.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, SEC Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Share Sale, CEO, Beneficial Ownership